Human dental stem cells of the apical papilla associated to BDNF-loaded pharmacologically active microcarriers (PAMs) enhance locomotor function after spinal cord injury

Kandalam, Saikrishna; Berdt, Pauline De; Ucakar, Bernard; Vanvarenberg, Kévin; Bouzin, Caroline; Gratpain, Viridiane; Diogenes, Aníbal; Montero‐Menei, Claudia N.; Rieux, Anne des

doi:10.1016/j.ijpharm.2020.119685

Cited by 17 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Na-alginate solution was used as the shell fluid in the device structure, whereas the Na-CMC solution was used as the inner-core fluid for the full delivery of drugs or cell culture. Kandalam et al (2020) [244] used Na-CMC as a potential vehicle for pharmacologically active microcarriers containing stem cells from the apical papilla and brain-derived neurotrophic factors, which was proposed as a possible therapy for spinal cord injury. Ahmadi et al (2011) [245] used a diluted solution (2.3% w/v) of Na-CMC to enhance the cell viability of their fabricated micro-spherical polylactide-co-glycolide carrier.…”

Section: D Bioprinting Processmentioning

confidence: 99%

Recent Developments of Carboxymethyl Cellulose

et al. 2021

View full text Add to dashboard Cite

Carboxymethyl cellulose (CMC) is one of the most promising cellulose derivatives. Due to its characteristic surface properties, mechanical strength, tunable hydrophilicity, viscous properties, availability and abundance of raw materials, low-cost synthesis process, and likewise many contrasting aspects, it is now widely used in various advanced application fields, for example, food, paper, textile, and pharmaceutical industries, biomedical engineering, wastewater treatment, energy production, and storage energy production, and storage and so on. Many research articles have been reported on CMC, depending on their sources and application fields. Thus, a comprehensive and well-organized review is in great demand that can provide an up-to-date and in-depth review on CMC. Herein, this review aims to provide compact information of the synthesis to the advanced applications of this material in various fields. Finally, this article covers the insights of future CMC research that could guide researchers working in this prominent field.

show abstract

Section: D Bioprinting Processmentioning

confidence: 99%

Recent Developments of Carboxymethyl Cellulose

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The nonlinearity of the BBB score complicates discerning improvement degrees, especially in patients with substantial motor function [ 107 ]. Despite increased neural markers in some in vitro experiments, more in vivo experiments are needed to confirm neural cell replacement [ 101 ]. Further research is needed to elucidate how dental stem cells comprehensively promote neuroregeneration, optimal strategies for combination with other modalities, and the biological safety of co-applying with biomaterials [ 101 ] Studies on SCAP and hydrogels show inconclusive results, contrasting with SHED treatment [ 95 ].…”

Section: Discussionmentioning

confidence: 99%

“…In another study, researchers encapsulated recombinant BDNF nano-precipitates in PLGA-P188-PLGA microspheres (BDNF-PAM) and implanted SCAP-derived stem cells into PAM. The SCAP BDNF-PAM treatment significantly increased cell retention in the spinal cord, improved motor coordination, reduced inflammation, and promoted axon growth, marking a novel injectable cell delivery system’s benefits in the SCI treatment [ 101 ].…”

Section: Treatment Approachesmentioning

confidence: 99%

Advancements in Spinal Cord Injury Repair: Insights from Dental-Derived Stem Cells

Wen,

Jiang,

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Spinal cord injury (SCI), a prevalent and disabling neurological condition, prompts a growing interest in stem cell therapy as a promising avenue for treatment. Dental-derived stem cells, including dental pulp stem cells (DPSCs), stem cells from human exfoliated deciduous teeth (SHED), stem cells from the apical papilla (SCAP), dental follicle stem cells (DFSCs), are of interest due to their accessibility, minimally invasive extraction, and robust differentiating capabilities. Research indicates their potential to differentiate into neural cells and promote SCI repair in animal models at both tissue and functional levels. This review explores the potential applications of dental-derived stem cells in SCI neural repair, covering stem cell transplantation, conditioned culture medium injection, bioengineered delivery systems, exosomes, extracellular vesicle treatments, and combined therapies. Assessing the clinical effectiveness of dental-derived stem cells in the treatment of SCI, further research is necessary. This includes investigating potential biological mechanisms and conducting Large-animal studies and clinical trials. It is also important to undertake more comprehensive comparisons, optimize the selection of dental-derived stem cell types, and implement a functionalized delivery system. These efforts will enhance the therapeutic potential of dental-derived stem cells for repairing SCI.

show abstract

“…Moreover, the BDNF‐loaded polyelectrolyte complex nanoparticles are biologically active and enable the prolonged release of BDNF after 1 week in vitro, accompanied by increased expression of neural differentiation markers (Kandalam et al, 2017). In support of this in vitro finding, the pharmacologically active microcarriers (PAMs) releasing BDNF improve rat locomotor function by immunomodulation and neuroprotection in vivo (Kandalam et al, 2020). Recently, the exosome is emerging as a promising drug delivery vehicle, due to its nanoscale (30–200 nm in size), biocompatibility, high circulation stability, and biological barrier permeability (Chinnappan et al, 2020; Meng et al, 2020).…”

Section: Bdnf‐based Myelin Repair Strategies: Replacement and Revivalmentioning

confidence: 94%

Thirty years of BDNF study in central myelination: From biology to therapy

Xiao

2023

Journal of Neurochemistry

View full text Add to dashboard Cite

Being the highest expressed neurotrophin in the mammalian brain, the brain‐derived neurotrophic factor (BDNF) is essential to neural development and plasticity in both health and diseases. Following the discovery of BDNF by Yves‐Alain Barde in 1982, the main feature of BDNF's activity in myelination was first described by Cellerino et al. in 1997. Since then, genetic manipulation of the BDNF‐encoding gene and its receptors in murine models has revealed the contribution of BDNF to the myelinating process in the central nervous system (CNS). The series of BDNF or receptor mouse mutants as well as the BDNF polymorphism in humans have provided new insights into the roles that BDNF signaling plays in myelination in a complex manner. 2024 marks the 30th year of BDNF's research in myelination. Here, we share our perspective on the 30‐year history of BDNF in the field of CNS myelination from phenotyping to therapeutic development, focusing on genetic evidence regarding the mechanism by which BDNF regulates myelin formation and repair in the CNS. This review also discusses the current hypotheses of BDNF's action on CNS myelination: axonal‐ and oligodendroglial‐driven mechanisms, which may be ultimately activity‐dependent. Last, this review raises the challenges and opportunities of developing BDNF‐based therapies for neurodegenerative diseases, opening unanswered questions for future investigation.image

show abstract

Human dental stem cells of the apical papilla associated to BDNF-loaded pharmacologically active microcarriers (PAMs) enhance locomotor function after spinal cord injury

Cited by 17 publications

References 37 publications

Recent Developments of Carboxymethyl Cellulose

Recent Developments of Carboxymethyl Cellulose

Advancements in Spinal Cord Injury Repair: Insights from Dental-Derived Stem Cells

Thirty years of BDNF study in central myelination: From biology to therapy

Contact Info

Product

Resources

About